Clinical Trial Update: Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression: A Randomized Controlled Trial [Phase 3]

View source ↗

Summary

A Phase 3 randomized controlled trial evaluated 0.01%, 0.03%, and 0.05% atropine eye drops for slowing myopia progression; results completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• Atropine eye drops (atropine)

Snippet

Sponsor: Khyber Medical College, Peshawar | Conditions: Myopia Progression, Atropine | Phase 3 | Status: COMPLETED